Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections.
This strategic deal expands patients’ access to pegfilgrastim therapy in four countries of Egis. With this agreement Egis gained the exclusive rights to introduce the biosimilar medicine in Hungary, Romania, Lithuania and Latvia.
Egis strengthens European presence in the biosimilar area
Mon, Jan 13, 2020 3:45 PM
Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar.
Egis strengthens European presence in the biosimilar area
Mon, Jan 13, 2020 3:45 PM
Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar.
Your browser is out of date. Please, use an updated version!